
Title: Cancer Treatment Using proANP Peptides

Serial No.: 10/708,688
First Named Inventor: David L. Vesely

FIG. 1


Pro ANP Gene:





N - TERMINAL Pro ANP PEPTIDES

FIG. 2



Vessel dilator (\blacksquare), long acting natriuretic peptide (\bigcirc , LANP), kaliuretic peptide (\blacktriangledown), and atrial natriuretic peptide (ANP, \triangledown) compared to control (\bullet) adenocarcinoma cells.

FIG. 3




FIG. 4




FIG. 5




FIG. 6

Four Peptide hormones effects on mediators of apoptosis.

		<u>Control</u>	LANP	Vessel <u>Dilator</u>	Kaliuretic Peptide	<u>ANP</u>
Caspases	9	+	+	+	+	+
	3	+	+	+	+	+
	7	+	+	+	+	+
Cleaved	9	+	+	+	+	+
Caspases	3	+	+	+	+	+
	7	+	+	+	+	+
PARP		+	+	+	+	+
Cleaved PARP	·	+	+	+	+	+

LANP = long acting natricuretic peptide, ANP = atrial natriuretic peptide, PARP = poly (ADP-ribose) polymerase

Graded 0 to ++++, with ++++ being the strongest staining observed. This table illustrates that basal caspase activity was low (+) and not significantly enhanced in the pancreatic adenocarcinoma cells by any of the peptide hormones at their 1 μ M concentrations when examined by repeated analysis of variance.

First Named Inventor: David L. Vesely

FIG. 7

Step 2

